IOVA logo

Iovance Biotherapeutics Inc. (IOVA)

$7.53

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on IOVA

Market cap

$3.48B

EPS

-0.5

P/E ratio

--

Price to sales

20.38

Dividend yield

--

Beta

0.875291

Price on IOVA

Previous close

$7.55

Today's open

$7.53

Day's range

$7.26 - $7.78

52 week range

$2.08 - $15.37

Profile about IOVA

CEO

Frederick G. Vogt

Employees

975

Headquarters

Philadelphia, PA

Exchange

NASDAQ Global Market

Shares outstanding

462655151

Issue type

Common Stock

IOVA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on IOVA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

news source

GlobeNewsWire • 21 hours ago

news preview

Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb

Iovance Biotherapeutics NASDAQ: IOVA is preparing to seek a lung cancer indication for its cell therapy AMTAGVI in 2027 while expanding its melanoma treatment network and advancing studies in earlier-stage melanoma and rare sarcomas, executives said at a Jefferies event.

news source

MarketBeat • Nov 16, 2026

news preview

Iovance: The Lung Selloff Went Too Far For A Business Growing 77%

Iovance's Amtagvi had its best quarter, at $101.60 million, up 77%, and operating cash burn nearly stopped at -$4.47 million. Proleukin did half of the sequential jump. The lung update sank the stock 47.60% from October 28. Outside a subgroup drawn after the data came in, the response was 8.51%, below the 12.8% Iovance cites for docetaxel. My sum-of-the-parts rNPV for IOVA gives a fair value of $8.86 in the base case and $13.32 if Amtagvi beats its own target, against a price of $7.76.

news source

Seeking Alpha • Nov 16, 2026

news preview

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

news source

PRNewsWire • Nov 12, 2026

news preview

Iovance Biotherapeutics to Present at Upcoming Conference

PHILADELPHIA, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conference: 2026 Jefferies Global Healthcare Conference in LondonFireside Chat: November 16, 2026, at 11:00 a.m. GMT / 6:00 a.m.

news source

GlobeNewsWire • Nov 12, 2026

news preview

Biotech Is Booming; Here Are 4 Names Outperforming Despite This Deep Correction

I build my biotech investments using technical analysis, focusing on price action and volume, not traditional fundamentals. I target small-cap biotechs advancing past Phase 2, especially those addressing hard-to-treat diseases with novel approaches. Recent regulatory headwinds have eased, derisking select names and enabling ground-floor entry after a sector-wide sell-off.

news source

Seeking Alpha • Nov 9, 2026

news preview

Iovance Q3 Earnings: Why I'm Reiterating My Buy Call Despite Market Reaction

Iovance Biotherapeutics, Inc., delivered strong Q3 results, with revenues up ~80% YoY and gross margin rising to 60%. IOVA reaffirmed 2026 guidance of $410–$420M revenue, and maintains a robust cash position ($376M) expected to last into 2029. Amtagvi's market-leading durability and expanding treatment center network support its competitive positioning despite intense oncology competition.

news source

Seeking Alpha • Nov 6, 2026

news preview

IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline Progress

Iovance reaffirms its 2026 revenue outlook as Q3 sales jump 80%, fueled by Amtagvi adoption, improving margins and progress in its cancer pipeline.

news source

Zacks Investment Research • Nov 6, 2026

news preview

IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs

Iovance beat Q3 2026 earnings and revenue estimates as Amtagvi sales top $100 million, margins improve and R&D costs decline.

news source

Zacks Investment Research • Nov 6, 2026

news preview

Iovance: Reset Expectations Make The Stock A Buy Again (Rating Upgrade)

Iovance Biotherapeutics, Inc. fell 46% after my downgrade to Hold in September, reflecting over-optimism in valuation. AMTAGVI's (lifileucel) melanoma launch gained momentum, but the NSCLC opportunity appeared overestimated based on Q2 call signals. Recent NSCLC data showed a 24.6% ORR across 69 evaluable patients, slightly below the prior interim readout.

news source

Seeking Alpha • Nov 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Iovance Biotherapeutics Inc.

Open an M1 investment account to buy and sell Iovance Biotherapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in IOVA on M1